🍪 Cookies

We use cookies to store, access and process personal data to give you the best online experience. By clicking Accept Cookies you consent to storing all cookies and ensure best website performance. You can modify cookie preferences or withdraw consent by clicking Cookie Settings. To find out more about cookies and purposes, read our Cookie Policy and Privacy Notice.

Cookies settings

Cookie Control

What are cookies?

Cookies are small text files that enable us, and our service provides to uniquely identify your browser or device. Cookies normally work by assigning a unique number to your device and are stored on your browser by the websites that you visit as well as third-party service providers for those website. By the term cookies other technologies as SDKs, pixels and local storage are to be considered.

If Enabled

We may recognize you as a customer which enables customized services, content and advertising, services effectiveness and device recognition for enhanced security
We may improve your experience based on your previous session
We can keep track of your preferences and personalize services
We can improve the performance of Website.

If Disabled

We won't be able to remember your previous sessions, that won't allow us to tailor the website according to your preferences
Some features might not be available and user experience reduced without cookies

Strictly necessary means that essential functions of the Website can not be provided without using them. Because these cookies are essential for the properly working and secure of Website features and services, you cannot opt-out of using these technologies. You can still block them within your browser, but it might cause the disfunction of basic website features.

  • Setting privacy preferences
  • Secure log in
  • Secure connection during the usage of services
  • Filling forms

Analytics and performance tracking technologies to analyze how you use the Website.

  • Most viewed pages
  • Interaction with content
  • Error analysis
  • Testing and Measuring various design effectivity

The Website may use third-party advertising and marketing technologies.

  • Promote our services on other platforms and websites
  • Measure the effectiveness of our campaigns


Modified Pfizer/BioNTech vaccination against Covid mutation called Omicron could be available soon enough. In the words of CEO of BioNTech, Ugur Şahin, „We can deliver in a very timely manner.” This event is favourable in both financial and technological ways.


On the other hand, Moderna - one of the biggest competitors - is suing both partner firms. Covid vaccination developers had been accused of patent infringement. Companies reportedly copied mRNA technology, which Moderna developed. The lawsuit was filed in US and Germany. However, Pfizer would “vigorously defend” itself against all the allegations. It is hard to judge the situation this soon or predict damage, this might cause. It is worth bearing in mind, this situation has only one winner.



“With our strong performance year to date, we believe to be well on track to achieve our previous financial guidance for the ongoing financial year,” said Jens Holstein, CFO of BioNTech. [1] In the chart below you can see Key Q2 Financial Results of BioNTech.

Snímek obrazovky 2022-10-10 v 11.08.29

Top sixth European technological company - according to BCMcomparison - has stock price, despite macroeconomics insecurities. BNTX price in the chart below is fluctuating in the past six months and recent lawsuit will may have the biggest influence in determination of the future price movements. * [2]

Graf biontech*

In spite of all that, BioNTech is long-termly, naturally growing company with great EPS ratio ($6.87) in the second quarter of 2022 and, has signed and agreement with U.S. government to provide vaccine doses, commenced construction of vaccine manufacturing facility in Africa etc. In other words, BioNTech is not going to disappear.



Biopharmaceutical New Technologies is a German company known for research and development of vaccines and medicaments based on mRNA. BioNTech has developed the Covid-19 mRNA based vaccination partnering with Pfizer in 2020. Since then, seemingly endless fight against Covid-19 and its mutations, became number one interest of the company.


In October 2019 the German, soon to become, giant got to be publicly traded on NASDAQ under the ticker, BNTX. BioNTech generated total gross proceeds of $150 million from the IPO.


* Past performance is no guarantee of future results.

[1,2] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate, or based on the current economic environment which is subject to change. Such statements are not guaranteeing of future performance. They involve risks and other uncertainties which are difficult to predict. Results could differ materially from those expressed or implied in any forward-looking statements.


Go back

The content of this material constitutes marketing communication and should not be considered as any type of investment advice and/or investment research and/or a solicitation for any transactions. This material was prepared for informational/educational purposes only and does not imply an obligation to perform investment transactions nor does it guarantee or predict future performance. BCM Begin Capital Markets Cy Ltd and its relevant persons including affiliates, agents, directors, or employees do not guarantee the accuracy, validity, timeliness, or completeness of any information/data provided by third parties and assume no liability for any loss arising from any investment made based on the said information/data. Past performance is no guarantee of future results.

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.06% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please read the Risk Disclosure.

BCM Begin Capital Markets Cy Ltd. currently does not accept registrations from Slovenian nationals or residents.